Intravenous administration of an oncolytic virus (cf33) engineered to express a nonsignaling CD19 antigen (CD19t) effectively infected and expressed CD19t in pancreatic tumors, triggering cell killing and increased immunogenic response by CD19-CAR T cells. Combination therapy of virus+CAR T cells led to significant tumor regression in pancreatic cancer models.
Journal Article by Chen C, Park AK (…) Fong Y et 5 al. in J Am Coll Surg
Copyright © 2024 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.